MedPath

The efficacy of combination therapy of toltrodine and tamsulosin on urinary symptoms

Phase 3
Completed
Conditions
rinary symptoms caused by stent.
Registration Number
IRCT20190119042410N1
Lead Sponsor
Boushehr University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
50
Inclusion Criteria

Patients over 18 years of age
Completion of written consent form
One-way ureteral stenting after ureteroscopy and TUL for ureteral stones
Negative urine culture prior to TUL and stents
male

Exclusion Criteria

Physician diagnosed sensitivity to tamsulosin, toltrodine or folic acid
Establishment of ureteral stent during the last 6 months

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Score from the USSQ Questionnaire. Timepoint: Start studying and two weeks later. Method of measurement: USSQ Questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath